DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Melinda Wharton - 1 Novavax - 1 John Jacobs - 1 Peter Marks - 1 David Kaslow - 1
Top related locs:
U.S Novavax
Top related orgs:
. Food - 1 Centers for Disease Control - 1 Advisors - 1 Pfizer - 1 Moderna - 1 National Center - 1 FDA - 1 CDC - 1

Search resuls for: "David Kaslow"


2 mentions found


☆ FDA advisors recommend that new Covid vaccines target an omicron XBB variant this fall
  + stars: | 2023-06-15 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
The committee unanimously voted that the new jabs should be monovalent — meaning they are designed to protect against one variant of Covid — and target a member of the XBB family. Those strains of Covid are descendants of the omicron variant, which caused cases to surge to record levels early last year. Advisors also generally agreed that the new shots should specifically target a variant called XBB.1.5. There is also uncertainty about which age groups the FDA and CDC will advise to receive the updated shots this fall. But it's unclear how many Americans will roll up their sleeves to take the updated shots later this year.
Persons: Melinda Wharton, Novavax, John Jacobs, Peter Marks, David Kaslow Organizations: . Food, Centers for Disease Control, Advisors, Pfizer, Moderna, National Center, FDA, CDC, Novavax, omicron Locations: U.S, Novavax
☆ FDA advisors recommend Pfizer RSV vaccine for older adults, despite possible Guillain-Barre risks
  + stars: | 2023-02-28 | by ( Spencer Kimball | ) www.cnbc.com   time to read: +5 min
The vote followed concerns at the FDA and among advisory committee members about two cases of Guillain-Barre syndrome among about 20,000 vaccine recipients. The FDA has asked Pfizer to conduct a safety study on Guillain-Barre syndrome, which the company has agreed to do. There currently is no approved RSV vaccine for the elderly. Pfizer's vaccine contains both strains of RSV, which circulate at the same time during fall and winter. Dr. David Kaslow, a senior official in the FDA's vaccine division, said safety monitoring will be "critically important" if Pfizer's RSV vaccine is approved.
0 next >>
Total: 2